Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL NEUROPATHY PAIN TREATMENT INDUSTRY
2.1 Summary about Neuropathy Pain Treatment Industry
2.2 Neuropathy Pain Treatment Market Trends
2.2.1 Neuropathy Pain Treatment Production & Consumption Trends
2.2.2 Neuropathy Pain Treatment Demand Structure Trends
2.3 Neuropathy Pain Treatment Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Calcium channel alpha 2-delta ligands
4.2.2 Serotonin-norepinephrine reuptake inhibitors
4.2.3 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Retail Pharmacies
4.3.2 Hospitals
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Calcium channel alpha 2-delta ligands
5.2.2 Serotonin-norepinephrine reuptake inhibitors
5.2.3 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Retail Pharmacies
5.3.2 Hospitals
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Calcium channel alpha 2-delta ligands
6.2.2 Serotonin-norepinephrine reuptake inhibitors
6.2.3 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Retail Pharmacies
6.3.2 Hospitals
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Calcium channel alpha 2-delta ligands
7.2.2 Serotonin-norepinephrine reuptake inhibitors
7.2.3 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Retail Pharmacies
7.3.2 Hospitals
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Calcium channel alpha 2-delta ligands
8.2.2 Serotonin-norepinephrine reuptake inhibitors
8.2.3 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Retail Pharmacies
8.3.2 Hospitals
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Calcium channel alpha 2-delta ligands
9.2.2 Serotonin-norepinephrine reuptake inhibitors
9.2.3 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Retail Pharmacies
9.3.2 Hospitals
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Pfizer
10.1.2 Depomed
10.1.3 Eli Lilly
10.1.4 Endo
10.1.5 Grünenthal Group
10.1.6 Arbor Pharmaceuticals
10.2 Neuropathy Pain Treatment Sales Date of Major Players (2017-2020e)
10.2.1 Pfizer
10.2.2 Depomed
10.2.3 Eli Lilly
10.2.4 Endo
10.2.5 Grünenthal Group
10.2.6 Arbor Pharmaceuticals
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
